Trial Profile
Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 04 May 2016 Time frame for primary endpoint changed from 2-3 years to 1-2 years.
- 04 May 2016 Time frame for primary endpoint changed from 2-3 years to 1-2 years.
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.